Cargando…

Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation

Apatinib is a new oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2. It has been proven effective in treating multiple solid tumors. Herein, we report the case of a 67-year-old Chinese patient who was diagnosed with recurrent and malignant transformation of in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yongguang, Mai, Weiheng, Chen, Weifeng, Yang, Chao, Li, Mingyi, Liu, Lijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273731/
https://www.ncbi.nlm.nih.gov/pubmed/34262864
http://dx.doi.org/10.3389/fonc.2021.676092
_version_ 1783721427365527552
author Yang, Yongguang
Mai, Weiheng
Chen, Weifeng
Yang, Chao
Li, Mingyi
Liu, Lijuan
author_facet Yang, Yongguang
Mai, Weiheng
Chen, Weifeng
Yang, Chao
Li, Mingyi
Liu, Lijuan
author_sort Yang, Yongguang
collection PubMed
description Apatinib is a new oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2. It has been proven effective in treating multiple solid tumors. Herein, we report the case of a 67-year-old Chinese patient who was diagnosed with recurrent and malignant transformation of intrahepatic biliary cystadenoma. After multidisciplinary team discussion, the team considered that the remaining liver volume was insufficient for surgical resection. The patient refused chemotherapy and radiotherapy and was willing to take apatinib. Initially, the patient experienced severe tongue ulcers and difficulty eating. The dose of apatinib was then adjusted to 250 mg/day. To date, he has been taking apatinib for 48 months. Regular re-examination showed that the tumor had significantly decreased in size. On January 16, 2021, a CT scan revealed a tumor diameter of 4.5 cm. In our case, the patient achieved partial response and progression-free survival(PFS) of 48.0 months. During treatment, the patient’s appetite and mental state were expected. The treatment did not induce hypertension, fatigue, hand-foot syndrome, or liver and kidney damage. Apatinib may be an option for the treatment of advanced intrahepatic biliary cystadenocarcinoma. Its toxicity is controllable and tolerable. The exact curative effect still needs to be evaluated in more cases.
format Online
Article
Text
id pubmed-8273731
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82737312021-07-13 Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation Yang, Yongguang Mai, Weiheng Chen, Weifeng Yang, Chao Li, Mingyi Liu, Lijuan Front Oncol Oncology Apatinib is a new oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2. It has been proven effective in treating multiple solid tumors. Herein, we report the case of a 67-year-old Chinese patient who was diagnosed with recurrent and malignant transformation of intrahepatic biliary cystadenoma. After multidisciplinary team discussion, the team considered that the remaining liver volume was insufficient for surgical resection. The patient refused chemotherapy and radiotherapy and was willing to take apatinib. Initially, the patient experienced severe tongue ulcers and difficulty eating. The dose of apatinib was then adjusted to 250 mg/day. To date, he has been taking apatinib for 48 months. Regular re-examination showed that the tumor had significantly decreased in size. On January 16, 2021, a CT scan revealed a tumor diameter of 4.5 cm. In our case, the patient achieved partial response and progression-free survival(PFS) of 48.0 months. During treatment, the patient’s appetite and mental state were expected. The treatment did not induce hypertension, fatigue, hand-foot syndrome, or liver and kidney damage. Apatinib may be an option for the treatment of advanced intrahepatic biliary cystadenocarcinoma. Its toxicity is controllable and tolerable. The exact curative effect still needs to be evaluated in more cases. Frontiers Media S.A. 2021-06-28 /pmc/articles/PMC8273731/ /pubmed/34262864 http://dx.doi.org/10.3389/fonc.2021.676092 Text en Copyright © 2021 Yang, Mai, Chen, Yang, Li and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Yongguang
Mai, Weiheng
Chen, Weifeng
Yang, Chao
Li, Mingyi
Liu, Lijuan
Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation
title Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation
title_full Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation
title_fullStr Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation
title_full_unstemmed Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation
title_short Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation
title_sort case report: low-dose apatinib in the treatment of intrahepatic biliary cystadenoma with recurrence and malignant transformation
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273731/
https://www.ncbi.nlm.nih.gov/pubmed/34262864
http://dx.doi.org/10.3389/fonc.2021.676092
work_keys_str_mv AT yangyongguang casereportlowdoseapatinibinthetreatmentofintrahepaticbiliarycystadenomawithrecurrenceandmalignanttransformation
AT maiweiheng casereportlowdoseapatinibinthetreatmentofintrahepaticbiliarycystadenomawithrecurrenceandmalignanttransformation
AT chenweifeng casereportlowdoseapatinibinthetreatmentofintrahepaticbiliarycystadenomawithrecurrenceandmalignanttransformation
AT yangchao casereportlowdoseapatinibinthetreatmentofintrahepaticbiliarycystadenomawithrecurrenceandmalignanttransformation
AT limingyi casereportlowdoseapatinibinthetreatmentofintrahepaticbiliarycystadenomawithrecurrenceandmalignanttransformation
AT liulijuan casereportlowdoseapatinibinthetreatmentofintrahepaticbiliarycystadenomawithrecurrenceandmalignanttransformation